Grifols completes development of very high sensitivity molecular test to detect SARS-CoV-2 virus

6 May, 2020
The company has developed the test in record time in a global coordinated effort of its facilities in San Diego, Barcelona and Bilbao, and has recently received the authorization of the Spanish Medicines and Medical Devices Agency (AEMPS) for its use in blood, plasma and respiratory samples. It has a sensitivity equal or even superior to that of other molecular tests currently available, such as those based on PCR.

Thanks to this high sensitivity, the molecular test will also permit testing of pools of samples (pool strategy), multiplying the capacity of testing the population.

The TMA test is a complete and automated testing solution that includes all the reagents, from the preparation of the sample to getting a result. It is processed on Procleix┬« Panther┬« systems, each unit with an analysis capacity of more than 1,000 samples daily.